Global sales are up by 7.4% on the previous year. Despite this result 2012 was a really challenging year for Chiesi Hellas. The country continues to experience a recession (now almost 5 years), with a continuously decreasing GDP and a 25% rate of unemployment.
The pharmaceutical industry reacted negatively by reducing the number of jobs and investments. In this environment, Chiesi Hellas overhauled its management and organisation and took key business decisions including new co-promotion agreements. The expansion of the Company’s business in Cyprus with the launch of Foster also consolidated the affiliate-s commercial presence there. Although 2013 continues to look challenging because of the lasting recession, Chiesi Hellas has already designed its strategy to further develop synergies and communicate effectively with the medical community. We are confident that Business Development & Licensing activities and acquisitions, together with the drug promotion action plans, will drive the company towards a new record sales year and make its reputation in the Country.